Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature (2000)

Peer-Reviewed Study · Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prove A, Vermorken JB · January 2000

Pelgrims J et al., 2000-01: Case series of 12 patients with ifosfamide-induced encephalopathy, of whom 8 were treated with intravenous methylene blue at 6 x 50 mg/day and 4 recovered without it. A separate group received 4 x 50 mg/day as prophylaxis in later cycles.

Eight were treated with MB at a dose of 6 x 50 mg day(-1) intravenously (i.v.). Four recovered fully within 24 h, two recovered partially after 24 h and completely after 48 h while two recovered only after 72 h.

Pelgrims J et al., 2000-01: Case series of 12 patients with ifosfamide-induced encephalopathy, of whom 8 were treated with intravenous methylene blue at 6 x 50 mg/day and 4 recovered without it. A separate group received 4 x 50 mg/day as prophylaxis in later cycles. Study type: case series with literature review. N=12 encephalopathy cases among 52 ifosfamide-treated patients. Country: Belgium (Antwerp). Dose: 6 x 50 mg/day IV for treatment; 4 x 50 mg/day IV for prophylaxis in later cycles. Route: intravenous. Duration: 24-72 h to recovery. Comparator: 4 patients who did not receive MB (all recovered after 48 h) – a non-randomised comparison. Funder/COI: not stated in record. Maker: not stated. Note: the small uncontrolled design means the authors' conclusion that MB 'is an effective treatment' is not established by this series. Also filed as MTI-60, MTM-22, MTK-36 (claims C1, C4, C6, C8). Study type: uncontrolled series.